Article Correctness Is Author's Responsibility: TAVR Found to be Cost-effective Compared with SAVR in Intermediate Risk Patients with Aortic Stenosis

Analysis of the PARTNER 2A trial and the SAPIEN-3 Intermediate Risk registry found transcatheter aortic valve replacement (TAVR) to be highly cost-effective compared with surgical aortic valve replacement (SAVR) in intermediate surgical risk patients with aortic stenosis.